Apr 12, 2026 | FDA Rejects Replimune RP1 Again; Sun Pharma's $12B Organon Bid; Amgen TEPEZZA Subcutaneous Win

FDA issues second CRL for Replimune's melanoma therapy RP1 —stock drops 20%, single-arm trial debate sharpens. Sun Pharma's $12B all-cash bid for Organon, Amgen's 77% proptosis response in subcutaneous TEPEZZA Phase 3, Lilly launches Foundayo, and AACR 2026 preview.Visit us at www.thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, Replimune, RP1,vusolimogene oderparepvec, melanoma, complete response letter, Sun Pharma,Organon, acquisition, Amgen, TEPEZZA, teprotumumab, thyroid eye disease, EliLilly, Foundayo, GLP-1, Novo Nordisk, Wegovy, Immunovant, batoclimab, Invivyd,VMS063, measles, AACR 2026, Gilead, Tubulis, ADC, Neurocrine, Soleno, Insmed,brensocatib, Travere, FILSPARI, sparsentan, FSGS, BioNTech, trastuzumabpamirtecan, Merck, Terns Pharmaceuticals, Roche, C4 Therapeutics, Lilly,AstraZeneca